Journal
CELL REPORTS
Volume 35, Issue 7, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.109124
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) KAKENHI [JP17H01390, JP16H06527, JP16K21734, JP16H06279]
- AMED [JP21ek0109411, JP25mg1310008]
- Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP [27-7, 30-9]
- JSPS KAKENHI [JP16J03827, JP19K16918, JP19H05211, JP18K06484, JP16K18391]
- NPO the Rett Syndrome Support Organization [2019-01-09, 2019-2-10]
Ask authors/readers for more resources
This study reveals the mechanism of MeCP2/miR-199a axis in regulating neural stem cell differentiation, further confirming the importance of BMP signaling in RTT brain development, and proposing the MeCP2/miR-199a/Smad1 axis as a potential therapeutic target for RTT.
Rett syndrome (RTT) is a severe neurological disorder, with impaired brain development caused by mutations in MECP2; however, the underlying mechanism remains elusive. We know from previous work that MeCP2 facilitates the processing of a specific microRNA, miR-199a, by associating with the Drosha complex to regulate neuronal functions. Here, we show that the MeCP2/miR-199a axis regulates neural stem/precursor cell (NS/PC) differentiation. A shift occurs from neuronal to astrocytic differentiation of MeCP2- and miR-199a-deficient NS/PCs due to the upregulation of a miR-199a target, Smad1, a downstream transcription factor of bone morphogenetic protein (BMP) signaling. Moreover, miR-199a expression and treatment with BMP inhibitors rectify the differentiation of RTT patient-derived NS/PCs and development of brain organoids, respectively, suggesting that facilitation of BMP signaling accounts for the impaired RTT brain development. Our study illuminates the molecular pathology of RTT and reveals the MeCP2/miR-199a/Smad1 axis as a potential therapeutic target for RTT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available